Indian pharmaceutical and healthcare firms are set for a significant fundraising push, aiming to garner ₹12,000-13,000 crore through IPOs in the coming months. Approximately fifteen companies are expected to enter the primary market, with fertility and women’s health segments particularly in focus.
Vedanta Aluminium at earnings inflection point? Here’s why Motilal Oswal sees 21% upside
Motilal Oswal has reiterated its Buy rating on Vedanta Aluminium Metal with a target price of Rs 540, implying 21% upside. The brokerage expects EBITDA